Siroz etiyolojisinde steatohepatitin yeri nedir?
Öz
Anahtar Kelimeler
Kaynakça
- 1. Cabibbo G, Palmeri L, Palmeri S, Craxì A. Should cirrhosis change our attitude towards treating non-hepatic cancer? Liver Int 2012;32:21-7. 2. Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and de¬pendence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend 2004;74:223-34. 3. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000;31:1014-8. 4. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15:1356-61. 5. Ökten A. Karaciğer sirozu. In: Büyüköztürk K, Atamer T, Dilmener M, eds. İç Hastalıkları Cilt-1, 1st edn. Ankara: No¬bel Tıp Kitabevi, 2007:1077-88. 6. Voiculescu M, Nanau RM, Neuman MG. Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma. J Gastrointestin Liver Dis 2014;23:425-9. 7. Ferolla SM, Armiliato GNA, Couto CA, Ferrari TCA. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liverdisease. Nutrients 2014;6:5583-99. 8. Paolella G, Mandato C, Pierri L, et al. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:15518-31. 9. Patel YA, Berg CL, Moylan CA. Nonalcoholic fatty liver disease: key considerations before and after liver transplantation. Dig Dis Sci 2016;61:1406-16. 10. Kew MC. Obesity as a cause of hepatocellular carcinoma. Ann Hepatol 2015;14:299-303. 11. Galper BZ, Wang YC, Einstein AJ. Strategies for primary prevention of coronary heart disease based on risk stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--Effectiveness Modeling Study. PLoS One 2015;10:e0138092. 12. Seçkin Y, Gülşen MT, Kantarçeken B, Dülger AC, Uyanıkoğlu A. Doğu ve Güneydoğu Anadolu Bölgesindeki sirozlu olguların değerlendirilmesi. 11. Hepato-Gastroenteroloji Kongresi, Bildiri Kitabı. 25-30 Eylül 2014, Kıbrıs, P-213, 103. 13. Başyiğit S, Asiltürk Z, Sapmaz F, et al. Hepatitis B virus is still the most common etiologic factor of liver cirrhosis: Results from a single center in Turkey. Dicle Med J 2015;42:416-21. 14. Erkal T. Non alkolik yağlı Karaciğer hastalığının (Nonalcoholic Fatty Liver Disease, NAFLD) siroz panelindeki Yeri. Uzmanlık Tezi, Haseki Eğitim ve Araştırma Hastanesi, İstanbul, 2008. 15. Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 2015;21:4103-10. 16. Çolak Y, Tuncer İ. Nonalcoholic fatty liver disease and steatohepatitis. J Ist Faculty Med 2010;73:85-91. 17. Yılmaz Ö, Kasap E, Yüceyar H. Four-year evaluation and association between chronic liver disease and diabetes mellitus in a patient. Akademik Gastroenteroloji Dergisi 2012;11:18-23. 18. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-73.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yazarlar
Ahmet Uyanıkoğlu
*
Bu kişi benim
0000-0003-4881-5244
Türkiye
Yayımlanma Tarihi
29 Nisan 2019
Gönderilme Tarihi
3 Şubat 2019
Kabul Tarihi
15 Nisan 2020
Yayımlandığı Sayı
Yıl 2020 Cilt: 19 Sayı: 1